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Introduction
　Arachidonic acid metabolites, collectively referred to 
as eicosanoids, include hydroxyeicosatetraenoic acids, 
prostaglandins, thromboxanes, and leucotrienes, and af-
fect a number of signal transduction pathways that 
modulate the growth and differentiation of various can-
cer cells1-3.  Cyclooxygenase（COX）is the rate-limiting 
enzyme for the production of prostaglandins and throm-
boxanes from free arachidonic acid（Fig. 1）4.  Two 
forms of COX have been described : a constitutive en-
zyme（COX-1）present in most cells and tissues ; and 
an inducible isoenzyme（COX-2）expressed in response 
to cytokines, growth factors, and other stimuli5.  It is re-
ported that more than 80% of human colon cancers ex-
hibit increased COX-2 levels when compared with adja-
cent normal tissue6.  Increased COX-2 expression has 
been conﬁ rmed in carcinomas of various organs in addi-
tion to colorectal cancer, including the prostate, lung, 
esophagus, pancreas, and mucous membranes of the 
head and neck7-11.  Previous studies have also demon-
strated that the overexpression of COX-2 plays an im-
portant role in angiogenesis, resistance to apoptosis, 
and suppression of host immunity12，13.  Inhibitors of 
COX-2 are thus believed to be effective chemopreventive 
agents against various types of cancer.  In this review, 
the relationship between COX-2 and carcinogenesis, 
with a focus on the effects of COX-2 inhibition against 
oral squamous cell carcinoma cells, is discussed.  We 
also review the future directions in the study of COX-2 
as a therapeutic target in cancer management. 
Human oral cancers and COX-2
　More than 300,000 new cases worldwide are being di-
agnosed as oral squamous cell carcinoma annually. 
This aggressive epithelial malignancy is associated with 
a high mortality and severe morbidity among the long-
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term survivors.  Tobacco smoke is one of the most domi-
nant risk factors for carcinogenesis of oral mucosa. 
COX-2 is induced by procarcinogens found in tobacco 
smoke, such as benzo［a］pyrene, and in turn, its peroxi-
dase activity can convert these chemicals into highly re-
active mutagens capable of binding to DNA14.  This 
mechanism could be particularly relevant at sites such 
as the oral cavity that are exposed to tobacco smoke, 
and suggests a potential role for COX-2 inhibition in 
preventing tobacco-related DNA damage.  Betel quid 
chewing is also known as an etiologic factor of oral leu-
koplakia, submucous fibrosis, and oral squamous cell 
carcinoma, and approximately 200 million persons chew 
betel regularly throughout the western Pacific basin 
and south Asia15.  Several lines of data revealed that the 
betel quid ingredients induce COX-2 expression in hu-
man oral keratinocytes16-18.
　The overexpression of COX-2 in head and neck squa-
mous cell carcinoma（SCC）has been documented by 
Chan and colleagues19.  In that report, tumors from 24 
patients and oral mucosa from 17 healthy volunteers 
were assessed by reverse transcription-polymerase 
chain reaction assay to examine the level of COX-2. 
The expression of COX-2 was increased 150-fold in tu-
mor cases and 50-fold in normal-appearing epithelium 
adjacent to the tumor compared with the expression in 
normal oral mucosa from healthy volunteers. Immuno-
histochemical analysis also revealed that the COX-2 
protein was expressed in both SCC and adjacent nor-
mal-appearing epithelium.  Renkonen et al. focused 
their study on the COX-2 expression level in human 
tongue carcinoma and its precursor lesions20.  The study 
revealed that the immunohistochemical evidence of the 
expression of the COX-2 protein in oral mucosal lesions 
increased from hyperplasia to dysplasia and was high-
est in SCC.  
　The ability to intervene before the advanced stage 
may improve treatment results.  This requires the early 
identification of molecular events that represent early 
phases of malignant transition, which is possible 
through measurement of DNA ploidy in epithelial cells 
of oral leukoplakia.  Sudbo et al. reported that DNA an-
euploidy was observed in epithelial cells of oral leuko-
plakia and that the ratio of the aneuploidy was highly 
correlated with the expression of aberrant COX-2 21，22.
Mechanisms by which COX-2 contributes to carci-
nogenesis
　COX-2, a bifunctional enzyme that has both peroxi-
dase and cyclooxygenase activities, can affect multiple 
mechanisms that are important in carcinogenesis.  Tsu-
jii et al. reported that overexpression of the COX-2 gene 
alters cell adhesion, inhibits apoptosis, and alters the 
response to growth regulatory signals23.
　A vascular supply to deliver nutrients and oxygen is 
essential to the development of a tumor mass.  Recently, 
levels of COX-2 were found to correlate with both vascu-
lar endothelial growth factor（VEGF）expression and 
tumor vascularization in head and neck cancers24.  This 
finding in human tissues is consistent with prior evi-
dence that overexpression of COX-2 in epithelial cells 
led to enhanced production of vascular growth factors 
and the formation of capillary-like networks25.  In addi-
tion, Nishimura et al. reported that a selective COX-2 
Fig. 1　Pathways of Arachidonic acid metabolism
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inhibitor suppressed angiogenesis in association with 
reduced growth of head and neck SCC xenografts in 
nude mice26.
　We previously reported that the COX-2 inhibitors 
NS-398 and nabumetone suppressed the proliferation of 
leukemia cell lines U-937 and ML-1 by inducing G0/G1 
cell cycle arrest27.  Cell cycle arrest induced by these 
COX-2 inhibitors was not associated with an up-regula-
tion of cyclin-dependent kinase inhibitors.  Inhibitors of 
COX-2 also inhibited the differentiation of these cells 
induced by interferon-gamma, tumor necrosis factor-al-
pha, and retinoic acid. Treatment with NS-398 did not 
suppress the levels of prostaglandins produced by these 
cells.  Although COX-2 antisense oligonucleotide 
showed a similar inhibitory effect on these cells, its in-
hibitory effect was smaller than that of NS-398.  These 
results suggest that COX-2 inhibitors may suppress the 
proliferation and differentiation of leukemia cells via 
both COX-2-dependent and COX-2-independent path-
ways.  We also reported that COX-2 was constitutively 
expressed in oral SCC cell lines NA and HSC-4, and 
that NS-398, a highly selective COX-2 inhibitor, sup-
pressed proliferation of these cells28.  Similar results 
were obtained from experiments using COX-2 antisense 
oligonucleotide（Fig. 2）.  Both NS-398 and COX-2 anti-
sense oligonucleotide induced G0/G1 cell cycle arrest in 
NA cells via up-regulation of cyclin-dependent kinase 
inhibitor p21, but not by up-regulation of the other cy-
clin-dependent kinase inhibitors29.  Interestingly, Sub-
baramaiah et al. reported that wild-type p53, which 
plays an important role in cell cycle regulation, sup-
pressed COX-2 transcription.  These data suggest the 
possibility that p53 status is also a determinant of 
COX-2 expression30.  
　Despite several recent advances in cancer treatment, 
tumor metastasis continues to be a major problem in 
the clinical management of malignancies.  Although it 
has been reported that the COX-2 inhibitors suppress 
the invasiveness of various cancer cells31-34, the precise 
mechanism is still not clearly understood in SCC.  Re-
cently, we reported that the invasiveness of NA and 
HSC-4 oral SCC cell lines was suppressed by treatment 
with either NS-398 or COX-2 antisense oligonucleotide 
in a matrigel invasion assay（Table 1）35.  These anti-
COX-2 reagents down-regulated the secretion of matrix 
metalloproteinase-2（MMP-2）into culture supernatant 
as well as the expression of MMP-2 mRNA and protein. 
Membrane-type 1 matrix metalloproteinase（MT1-
MMP）, an activator of proMMP-2, was also down-regu-
lated by treatment with these reagents.  Furthermore, 
expression of CD44 on the surface of these cells was re-
duced by treatment with either NS-398 or COX-2 anti-
sense oligonucleotide.  These findings suggest that 
NS-398 and COX-2 antisense oligonucleotide suppress 
Fig. 2　Effect of COX-2 inhibition on the proliferation of OSCC cells. Oral squa-
mous cell lines, NA and HSC-4 cells, were seeded into 96-well microplates 
and allowed to adhere for 24 h. Both cells were then treated with NS-398
（79.5mM）or COX-2 antisense oligonucleotide（5 μM）for the periods in-
dicated. ＊Signiﬁ cantly different（p＜ 0.01）versus control.
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the invasiveness of oral SCC cells via down-regulation 
of MMP-2 and CD44.
In vivo studies : animal model
　To examine the involvement of COX-2 in carcinogene-
sis of oral epithelial cells, hamster buccal pouches are 
frequently used in in vivo studies.  Nishimura et al. re-
ported that COX-2 expression in hamster buccal pouch 
cells was up-regulated by treatment with 7, 12-dimeth-
ylbenz［a］anthracene.  The expression of COX-2 was re-
duced by treatment with celecoxib, a selective COX-2 
inhibitor, while the apoptotic cells were increased in the 
tumor parenchyma.  Moreover, angiogenesis in the stro-
ma was signiﬁ cantly reduced36.  Tongue carcinogenesis 
initiated with 4-nitroquinoline-1-oxide（4-NQO）in 
rats is also a frequently used animal model in cancer re-
search.  Yoshida et al. reported that the elevated expres-
sion of COX-2 in the 4-NQO-induced tongue SCC in rats 
was reduced by feeding the animals with nimesulide, a 
selective COX-2 inhibitor, while proliferating cell nucle-
ar antigen was reduced and apoptotic index was up-reg-
ulated37.  Similarly, Yamamoto et al. reported that the 
incidence and multiplicity of tongue SCCs induced by 
4-NQO were dose-dependently reduced in rats by feed-
ing them etodolac, a selective COX-2 inhibitor38-40. 
These studies show that selective COX-2 inhibitors 
have a potential role in the chemoprevention of oral 
SCC.
Use of COX-2 inhibition for oral cancers : future 
direction
　As described above, transcription of COX-2 is consti-
tutively up-regulated in several malignancies including 
oral cancer, and studies indicate that overexpression of 
COX-2 is associated with resistance to apoptosis, angio-
genesis, decreased host immunity, and enhanced inva-
sion and metastasis41-44. 
　Combination therapy, a common strategy in cancer 
treatment, may be equally applicable in chemopreven-
tion.  Low doses of combinations of agents may be more 
effective than the agent alone with less toxicity.  Dicker 
et al. indicated that selective COX-2 inhibitors enhance 
the suppressive effect of irradiation on proliferation, mi-
gration, and tube formation of endothelial cells45.  In ad-
dition, recent studies revealed that the selective COX-2 
inhibitor enhances radiation-induced cell death in hu-
man cancer46，47.  These evidences suggest that the com-
bination of COX-2 inhibitor and radiation will be an 
effective, complementary strategy in the clinical man-
agement of malignancies.  Aberrant expression of the 
growth factor receptor system and dysregulation of the 
downstream cell-signaling molecules have been reported 
in a wide range of epithelial tumors.  Inhibitors of epi-
dermal growth factor receptor（EGFR）have been ap-
proved for treatment of epithelial tumors and may have 
potential in the treatment of patients with head and 
neck cancers.  A recent study revealed that the combina-
tion of AZ1478 or ZD1839, EGFR-selective tyrosine ki-
nase inhibitors, with celecoxib either additively or syn-
ergistically inhibited the growth of head and neck SCC 
cell lines48.  Furthermore, COX-2 inhibitors have been 
shown to enhance the activity of chemotherapy in ex-
perimental models of several different malignancies and 
several human trials have been performed49-52.  Al-
though the COX-2 inhibition in cancer prevention and 
treatment has been shown in numerous experimental 
models, the clinical usage of COX-2 inhibition for cancer 
treatment should be carefully considered.  To be useful 
in humans, a chemopreventive agent must have an ac-
ceptable safety profile in addition to being effective. 
Endoscopically controlled studies revealed that selective 
COX-2 inhibitors caused less injury to the gastrointesti-
nal mucosa than classical nonsteroidal anti-inﬂ ammato-
ry drugs53.  On the other hand, Becerra et al. reported 
Table 1　Effects of NS-398 and COX-2 AS on invasiveness of OSCC cells.
treatment
Cell lines control N5-398 N5-398＋ PGE2 COX-2 A5 COX-2 A5＋ PGE2 PGE2
NA
HSC-4
100
100
70.24± 19.85－
69.16± 13.06－
86.85± 3.35
90.91± 3.59
64.83± 4.39－
62.27± 5.23－
84.32± 4.07
94.55± 6.93
110.59± 4.07
114.09± 4.37（%：mean± SD）
NA and HSC-4 cells were treated with NS-398（79.5 μM）or COX-2 AS（5 μM）, in the presence or absence of 10 μg/ml of PGE2. 
Following 18 h of incubation, invading cells were stained and counted. Five ﬁ elds were counted per ﬁ lter in each group. Values are 
the mean ± standard deviation（S.D.）of triplicate determinations. ＊p＜ 0.05, ＊＊p＜ 0.01 versus control.
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an increased toxicity of rofecoxib in combination with 
chemotherapy in patients with colorectal cancer54.
　Although further investigation focused on the side ef-
fects of COX-2 inhibition should be performed very care-
fully, genetic or pharmacological inhibition of COX-2 
will no doubt be a beneﬁ cial strategy, either alone or in 
combination with standard therapy, in the treatment of 
patients with oral cancer. 
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